CAR T-cell therapy

Researchers at CRISPR Therapeutics and Massachusetts General Hospital Cancer Center have joined forces to develop T-cell-based cancer immunotherapies using the CRISPR/Cas9 gene editing system. CRISPR/Cas9 allows researchers to alter or ... Read more

The leukemia of 83 percent of young patients treated with Novartis’ CTL019 was in remission three months after the therapy administered, and it lasted six months, researchers reported. There were ... Read more

Novartis is a step closer to the U.S. Food and Drug Administration approving its CAR T-cell therapy CTL019 for certain patients with leukemia. The FDA has accepted Novartis’ Biologics License Application for ... Read more

Researchers from the Fred Hutchinson Cancer Research Center talked about recent developments and new research findings in immunotherapy at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer ... Read more

The recent discovery of a new group of antibodies allowed researchers at the University of California, Los Angeles (UCLA), to engineer an immunotherapy with promise as a cancer treatment, CAR T-cell therapy, to be ... Read more

Disclaimer:

Immuno-Oncology News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.